AUTHORS
Jingtao Huang, PhD, Xiangqin Weng2, Zengkai Pan3, Chuanhe Jiang4, Luxiang Wang5, Zilu Zhang, MD6, Jiayu Huang, MD7, Haiyang LU8, Fang Dong, PhD9, Xiaoxia Hu, MD10
AFFILIATIONS
1 Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
9 Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
10 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
ABSTRACT
Introduction:
Acute graft-versus-host disease (aGvHD) remains a major complication after allogeneic hematopoietic cell transplantation (allo-HCT). Although T-cell activation drives tissue injury, early immune tolerance establishment after transplantation depends on coordinated reconstruction of multiple lymphoid compartments. Hematogones (HGs), transient B-cell precursors emerging during marrow regeneration, may reflect the quality of lymphoid developmental recovery. We investigated whether early HG maturation predicts immune tolerance and subsequent aGvHD risk after allo-HCT
Methods
We analyzed 400 allo-HCT recipients with acute myeloid leukemia or myelodysplastic syndromes (AML/MDS) undergoing first haploidentical HCT between May 2021 and December 2025.Cell phenotypes of fresh bone marrow (n = 400) or peripheral blood (n = 124) at day 30 post allo-HCT were analyzed by flow cytometry. HG1 was defined as CD34+CD10+CD38+ cells, while HG2 was defined as CD34-negative CD10+CD38+ cells. The HG-positive group was defined as patients whose BM aspiration sample contained 0.01% HGs or more. CD34+CD117+ cells represent primitive hematopoietic progenitors enriched for myeloid differentiation potential. Cumulative incidences of aGvHD were calculated using landmark methods. Additionally, time-dependent Cox proportional hazards models were used to identify the risk factors for aGvHD.
Results
Day-30 bone marrow analysis identified distinct patterns of early hematopoietic reconstruction. HG1 (CD34+CD10+CD38+) and CD34+CD117+ progenitors represented the predominant CD34+ subsets and showed an inverse correlation among total CD34+ cells (R=-0.69, P<0.001), suggesting divergent lymphoid versus primitive progenitor recovery trajectories.
Based on predominant CD34? populations, patients were classified into primitive progenitor-dominant (CD34?CD117? dominant, n = 217), B-lineage-dominant (HG1 dominant, n=95), and mixed reconstruction groups (n = 88). Landmark analysis demonstrated that primitive progenitor-dominant reconstruction was associated with a higher incidence of aGvHD before day 30 compared with B-lineage-dominant and mixed patterns (24% vs. 3.2% vs 8%, P < 0.001). In multivariable analysis, B-lineage-dominant (HR, 0.52; 95% CI, 0.30–0.91; P=0.021) and mixed reconstruction patterns (HR, 0.46; 95% CI, 0.30–0.68; P < 0.001) independently predicted reduced aGvHD risk.
Among patients with detectable HG1, subsequent HG2 maturation was associated with reduced inflammatory polarization, reflected by lower circulating Th1/Th17 subsets (0.44 vs 1.3 cells/μL; P=0.03). HG2-positive patients had a lower 180-day cumulative incidence of aGvHD than HG2-negative patients (29.3% vs 41.7%; P<0.001), and HG2 positivity remained independently protective (HR, 0.46; 95% CI, 0.30–0.68; P<0.001). Notably, HG2 recovery was not associated with peripheral B-cell recovery, suggesting that HG maturation reflects lymphoid developmental competence and immune tolerance restoration rather than mature B-cell abundance.
Conclusion
Early HG maturation reflects the quality of lymphoid immune reconstruction after allo-HCT. Persistence of primitive progenitor-dominant recovery identifies patients at increased risk of aGvHD, whereas B-lineage commitment is associated with reduced inflammatory polarization and improved immune tolerance. These findings establish hematogone maturation as an early biomarker for immune tolerance restoration and GVHD risk stratification after allo-HCT.
DISCLOSURES
Jingtao Huang, PhD: No relevant conflicts of interest to declare.